M&A Deal Summary

Repligen Acquires Tantti

On July 29, 2024, Repligen acquired life science company Tantti

Acquisition Highlights
  • This is Repligen’s 3rd transaction in the Life Science sector.
  • This is Repligen’s 1st transaction in Taiwan.

M&A Deal Summary

Date 2024-07-29
Target Tantti
Sector Life Science
Buyer(s) Repligen
Deal Type Add-on Acquisition
Advisor(s) O'Melveny & Myers (Legal)

Target

Tantti

Taoyuan, Taiwan
Tantti is a biomaterials engineering company developing bioprocessing solutions for use in the development and production of innovative biologic products and advanced cell and gene therapies. Its key product technology platforms include DuloCore, a new class of convective chromatography bead resin designed for the purification of large biomolecules (e.g., viral vectors, nucleic acids, and viruses). Tantti was formed in 2014 and is headquartered in Taoyuan, Taiwan.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Repligen

Waltham, Massachusetts, United States

Category Company
Founded 1981
Sector Life Science
Employees1,778
Revenue 634M USD (2024)
DESCRIPTION

Repligen is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Repligen was founded in 1981 and is based in Waltham, Massachusetts.


DEAL STATS #
Overall 11 of 11
Sector: Life Science M&A 3 of 3
Type: Add-on Acquisition M&A Deals 11 of 11
Country: Taiwan M&A 1 of 1
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-26 Metenova

Mölndal, Sweden

Metenova is a provider of critical products and solutions for the production of aseptic and sterile pharmaceuticals. Metenova operates globally with leading companies within pharmaceutical and biotech industries mainly through a distributor network. Metenova was established in 2009 and is based in Mölndal, Sweden.

Buy -